Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab +/- Ipilimumab in 2L Advanced NSCLC
NCT03430063Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2018
- Primary completion
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 9
01
Overview
A Phase 2 trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Regeneron Pharmaceuticals. Started May 2018; status: terminated.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03430063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430063.